tiprankstipranks
Ocular Therapeutix (OCUL)
NASDAQ:OCUL
Holding OCUL?
Track your performance easily

Ocular Therapeutix (OCUL) Ownership - Who Owns Ocular Therapeutix?

1,401 Followers

Ocular Therapeutix (OCUL) Ownership Overview

15.49%9.63%56.72%11.13%7.03%
15.49% Insiders
56.72% Other Institutional Investors
11.13% ETFs
7.03% Public Companies and
Individual Investors
The ownership structure of Ocular Therapeutix (OCUL) stock is a mix of institutional, retail, and individual investors. Approximately 77.48% of the company’s stock is owned by Institutional Investors, 15.49% is owned by Insiders, and 7.03% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 27, 2024
xxxxxxxxxxxxx
$16525
Aug 27, 2024
Pravin Dugel
Executive Chairman, President And Ceo,director
xxxxxxxxxxxxx
$188338
May 28, 2024
xxxxxxxxxxxxx
$13280
May 28, 2024
Pravin Dugel
Executive Chairman, President And Ceo,director
xxxxxxxxxxxxx
$125215

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$8700000

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
12,420,176Insider7.90%105,819,900
8,591,401Insider5.46%73,198,737
7,822,312Institution4.98%66,646,098
6,897,968Institution4.39%58,770,687
6,377,339Institution4.06%54,334,928
3,324,468Institution2.11%28,324,467
1,719,204Institution1.09%14,647,618
1,592,836Institution1.01%13,570,963
1,309,457Institution0.83%11,156,574
1,069,183Institution0.68%9,109,439

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
6,897,968Institution4.39%58,770,687
1,719,204Institution1.09%14,647,618
1,592,836Institution1.01%13,570,963
1,309,457Institution0.83%11,156,574
790,988Institution0.50%6,739,218
450,380Institution0.29%3,837,238
427,500Institution0.27%3,642,300
410,100Institution0.26%3,494,052
336,267Institution0.21%2,864,995
300,000Institution0.19%2,556,000

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
4,643,156Institution2.95%48,892,433
4,232,790Institution2.69%36,063,371
1,899,480Institution1.21%20,001,524
1,394,094Institution0.89%11,877,681
709,299Institution0.45%7,468,918
614,198Institution0.39%5,392,658
459,553Institution0.29%3,915,392
334,399Institution0.21%3,521,221
356,324Institution0.23%3,035,880
319,600Institution0.20%2,850,832

FAQ

Who Owns Ocular Therapeutix (OCUL)?
According to the latest TipRanks data, approximately 56.72% of the company's stock is held by institutional investors, 15.49% is held by insiders, and 7.03% is held by retail investors.
    What percentage of Ocular Therapeutix (OCUL) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 56.72% of Ocular Therapeutix (OCUL) stock is held by institutional investors.
      What percentage of Ocular Therapeutix (OCUL) stock is held by retail investors?
      According to the latest TipRanks data, approximately 7.03% of Ocular Therapeutix (OCUL) stock is held by retail investors.
        Who owns the most shares of Ocular Therapeutix (OCUL)?
        Behzad Aghazadeh owns the most shares of Ocular Therapeutix (OCUL).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis